RVU Stock Overview
A clinical-stage biopharmaceutical company, engages in developing of novel small molecule therapies for treatment in oncology. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Ryvu Therapeutics S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | zł46.00 |
| 52 Week High | zł67.10 |
| 52 Week Low | zł39.50 |
| Beta | 0.65 |
| 11 Month Change | -4.96% |
| 3 Month Change | -12.55% |
| 1 Year Change | -21.90% |
| 33 Year Change | -22.17% |
| 5 Year Change | 7.48% |
| Change since IPO | 751.85% |
Recent News & Updates
Recent updates
Despite Lacking Profits Ryvu Therapeutics (WSE:RVU) Seems To Be On Top Of Its Debt
Oct 20
We're Keeping An Eye On Ryvu Therapeutics' (WSE:RVU) Cash Burn Rate
Aug 02Are Investors Undervaluing Ryvu Therapeutics S.A. (WSE:RVU) By 20%?
Jan 25What Type Of Shareholders Own The Most Number of Ryvu Therapeutics S.A. (WSE:RVU) Shares?
Feb 05Shareholders Of Ryvu Therapeutics (WSE:RVU) Must Be Happy With Their 261% Total Return
Dec 14Shareholder Returns
| RVU | PL Life Sciences | PL Market | |
|---|---|---|---|
| 7D | 7.0% | -1.3% | -3.3% |
| 1Y | -21.9% | -15.7% | 1.1% |
Return vs Industry: RVU underperformed the Polish Life Sciences industry which returned -15.7% over the past year.
Return vs Market: RVU underperformed the Polish Market which returned 1.1% over the past year.
Price Volatility
| RVU volatility | |
|---|---|
| RVU Average Weekly Movement | 6.3% |
| Life Sciences Industry Average Movement | 5.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in PL Market | 8.6% |
| 10% least volatile stocks in PL Market | 3.0% |
Stable Share Price: RVU's share price has been volatile over the past 3 months compared to the Polish market.
Volatility Over Time: RVU's weekly volatility (6%) has been stable over the past year, but is still higher than 75% of Polish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 270 | Pawel Przewiezlikowski | www.ryvu.com |
Ryvu Therapeutics S.A., a clinical-stage biopharmaceutical company, engages in developing of novel small molecule therapies for treatment in oncology. Its lead candidate, RVU120, is a CDK8 kinase inhibitor with potential for development in hematological malignancies and solid tumors, which is in Phase 1b study for the treatment of acute myeloid leukemia and myelodysplastic syndrome. The company’s products also include SEL24/MEN1703, a dual PIM/FLT3 kinase inhibitor licensed to the Menarini Group that is in Phase 2 clinical trial for the treatment of acute myeloid leukemia.
Ryvu Therapeutics S.A. Fundamentals Summary
| RVU fundamental statistics | |
|---|---|
| Market cap | zł1.06b |
| Earnings (TTM) | -zł104.14m |
| Revenue (TTM) | zł91.18m |
11.7x
P/S Ratio-10.2x
P/E RatioIs RVU overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RVU income statement (TTM) | |
|---|---|
| Revenue | zł91.18m |
| Cost of Revenue | zł18.68m |
| Gross Profit | zł72.50m |
| Other Expenses | zł176.63m |
| Earnings | -zł104.14m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.50 |
| Gross Margin | 79.51% |
| Net Profit Margin | -114.21% |
| Debt/Equity Ratio | 45.3% |
How did RVU perform over the long term?
See historical performance and comparison